전환은 재설계입니다., 부가기능이 아닌
PAS-B 포켓을 점유하여 HIF-1α를 억제하는 고리형 펩타이드가 자물쇠 하나에 꼭 맞는 키컷입니다.. 분해기로 바꾸는 것은 해당 키에 손잡이를 용접하는 것을 의미합니다.: 링커와 VHL 모집 요소, 새로운 팔이 리가아제를 모집하기 위해 손을 뻗는 동안 링이 여전히 주머니에 안착되도록 배치됩니다.. 치아는 변할 수 없다. 다른 모든 것은 가능합니다.
그 차이가 전체 프로젝트를 주도합니다. 앵커의 경우, 링커와 VHL 리간드는 맞춤형 이작용성 아미노산으로 구축되었으며 고체상 펩타이드 합성 중에 직접 통합되었습니다., 고리화 후에 붙는 것보다 (잭, 순환 펩티드 PROTAC는 저산소증에서 VHL 매개 HIF-1α 분해를 복원합니다, 2026). 실질적인 결과는 부착 지점이 체인 조립 시 고정된 설계 선택이 된다는 것입니다., 나중에 벤치에서 조정하는 변수가 아닙니다..
모든 다운스트림 결정은 해당 약속에서 따릅니다.: 어떤 기울기가 공액을 해결하는지, 어떤 형태의 확인으로 반지가 살아남았는지 확인, 단순한 점유와 분해를 구별할 수 있는 분석법은 무엇입니까?.
링커를 전달해야 하는 출구 벡터?
접합 부위 선택은 이후의 모든 결정을 제한하는 첫 번째 결정입니다., 규칙은 간단합니다.: 결합을 방해할 가능성이 가장 적고 용매에 노출될 가능성이 가장 높은 위치를 선택합니다. (PROTAC 링커 설계를 위한 현재 전략, 2020). 표적에 결합된 고리형 펩타이드의 공결정 구조를 이용할 수 있는 경우, 그 규칙은 조사를 통해 답할 수 있다. 그렇지 않을 때, 검사는 문제를 결정할 수 없습니다, 그렇지 않은 척하는 것이 프로그램이 몇 달을 잃는 이유입니다.
서비스 부착 지점은 또한 펩타이드가 최적화된 후 추가하는 유도체화 단계가 아닙니다.. 체인 조립 디자인 선택입니다, 합성이 시작되기 전에 고정됨, 앵커 케이스에 있던 것처럼. 나중에 마음을 바꾸는 것은 펩타이드를 재합성하는 것을 의미합니다, 사이드 체인을 편집하지 않음.
경험적 순위 규칙: 각각이 보존하는 것에 따라 후보 벡터의 순위를 매깁니다., 이 순서대로: 타겟 선호도, 그런 다음 삼항 복잡한 동작, 그런 다음 저하. 용제에 노출된 것처럼 보이는 위치의 좁은 SAR은 경고입니다., 소음이 아닌. 그 위치는 구조적으로 하중을 견디는 위치입니다., 그리고 순위를 다시 정해야 해요.
링커 및 E3 요소 설치
경로 결정이 먼저입니다, On-Resin과 Solution conjugation이 서로 다른 위치에서 실패하기 때문입니다.. 이작용성 아미노산의 수지 내 설치는 사슬 자체에 링커를 구축합니다., 따라서 보호 그룹 체계는 다음을 통해 링커의 직교 핸들을 그대로 유지해야 합니다. 가게 모든 후속 커플링 및 고리화 단계. 고리화 후 솔루션 활용이 반복 속도가 더 빠릅니다., 그러나 유리 펩타이드를 활성화 화학에 두 번 노출시키고 반응성 잔기가 고유하지 않은 경우 위치 이성질체의 혼합물을 정제하게 됩니다..
Southampton의 연구는 그 반복이 무엇을 가져다 주는지 보여줍니다.. cyclo-CLLFVY로 시작된 시리즈가 2세대 탄두로 옮겨갔다, 사이클로-CLLF(CF3)만약에(브르), 나중에 추가되지 않고 서열에 내장된 더 긴 비천연 아미노산 링커를 운반합니다. (McDermottet al., 2025). 링커를 체인에 구축하는 것은 링커 길이를 정제 문제 대신 설계 변수로 만드는 것입니다..
이 경로에서 펩타이드 순도와 접힘에 대한 주요 위협은 에피머화이기 때문에 이는 중요합니다., 그리고 그것은 기계적으로 피할 수 있습니다. 아미노산을 활성화하면 α-탄소에서 일시적으로 비키랄성 평면형 옥사졸론이 형성됩니다., 따라서 재양성자는 L 중 하나를 반환할 수 있습니다.- 또는 D-구성. 활성화 기간이 연장되면 위험이 높아집니다., 반응성이 높은 커플링 시약, 그리고 축적된 활성화된 중간체, 및 페닐글리신과 같은 잔류물, 시스테인과 히스티딘은 특히 취약합니다. (바헴; 펩타이드 합성의 에피머화, 2023).
규모는 경로에 따라 다릅니다., and one vendor’s feasibility work illustrates the spread rather than setting a benchmark: fragment-route conjugation produced roughly 13% epimer formation and was discontinued, while the alternative route showed 2–3% epimerization rising to about 5% after purification, and linear SPPS gave the highest yield with no epimerization detected (바헴). Read that as a signal about which route classes carry the risk, not as a rate you can expect on your own sequence. 에 대한
RP-HPLC 순도 데이터로 알 수 있는 것과 알 수 없는 것
A single main-peak percentage at 214 nm confirms neither correct conjugation nor correct folding. It tells you that the UV-absorbing species in your sample elute as one band on one gradient. That is a useful fact, and it is a smaller fact than most programs treat it as.
For a larger, more hydrophobic conjugate, the method resolves less than it did for the parent cyclic peptide. The linker and E3 element add hydrophobic surface area, the retention time shifts, and species that were baseline-separated on the parent gradient start to co-elute. A published disulfide-cyclized peptide degrader program reports its preparative practice plainly: one RP-HPLC step on a 0.1% TFA water/acetonitrile gradient running 26–43% over 40 minutes at 10 mL/분, detection at 220 nm, oxidation monitored by mass spectrometry alongside HPLC, and a final HPLC quality check before lyophilization (Frontiers in Immunology, 2023). Note what that paper does not state: any purity threshold. The number is a process output, not a specification.
Suppliers commonly specify ≥95% RP-HPLC purity as the floor for biological evaluation, ≥98% for quantitative binding and dose-response work, and ≥99% for reference-standard work, with purity defined as main-peak area over total peak area by UV detection at 214–220 nm (GenScript; 창의적인 단백질체학, 2025). Treat those bands as purchasing convention rather than a measured finding about your molecule. They describe what a vendor will certify, not what your conjugate needs.
The gap matters because peptide purity and folding are different questions, and RP-HPLC answers only the first. A co-eluting epimer, a misfolded disulfide isomer, or an unreacted parent that happens to run at the same retention time all present as a clean single peak. Mass identity, 입체화학, and solution conformation each require an orthogonal method.
Read the matrix as a coverage check, not a ranking. RP-HPLC covers hydrophobicity and purity. LC-MS and HRMS cover mass identity, which is how you confirm the linker actually installed. Chiral LC covers stereochemistry, which is how you catch epimerization at the conjugation site. NMR and CD cover solution conformation, which is how you distinguish a folded conjugate from an unfolded one. No single row covers more than one column, and a program that reports only the first row has evidence for exactly one of four questions.
The practical consequence for conjugation-site selection: if your analytical package is one RP-HPLC trace, you cannot yet tell whether the exit vector you chose produced the conjugate you designed. Add the orthogonal methods before you commit the route, not after a binding assay comes back flat.
접힘 및 형태 검증
펩타이드 합성 Cyclization constrains the backbone, but it does not guarantee that the bioactive conformation survives linker addition. That distinction is why conformational evidence has to be orthogonal to purity evidence: each method class answers a question the others cannot.
Chiral LC resolves stereochemistry, so it tells you whether the conjugate racemized at the residues you care about. CD reports on solution secondary structure, and NMR reports on the specific contacts that define the bound fold. None of these substitutes for another, and none of them substitutes for a functional readout. The same principle governs the assay stage: a ternary-complex signal alone is insufficient, and cellular DC50/Dmax values alone are phenotypic rather than mechanistic (Methods to Study the Molecular Mechanism and Drive the Design of Degraders, 검색됨 2026-05-14).
핵심 내용: High HPLC purity is not correct conjugate. A peak that is clean and mass-confirmed can still carry the wrong fold into the assay stage.
For your data package, that gap is the risk to close. A conjugate that passes purity and mass identity but was never conformationally checked carries an unquantified risk forward, and the assay team inherits it. Treat peptide purity and folding as two separate evidence lines, each with its own method and its own acceptance criterion, before the material is released to biology.
기능적 분석 증거 체인
A degradation claim is a mechanism claim, and no single assay carries it. The evidence chain has four links, and a reviewer will look for all four: ternary complex formation, target ubiquitination, proteasomal dependence, and a quantitative potency and ceiling readout. If your package stops after the first link, you have shown binding, not degradation.
Work down the chain against your own data. Ternary complex: a co-crystal or a biophysical assay showing target, PROTAC and E3 ligase in one assembly. 유비퀴틴화: a direct or indirect readout that the target itself acquires ubiquitin. Proteasomal dependence: rescue by a proteasome inhibitor. Potency and ceiling: DC50 and Dmax from the same dose-response series.
The third link is the one most often skipped, and it is cheap to close. In the cyclic peptide work, PD-L1 loss at 2.5 µM after 4 hours was blocked by MG132, which is what separates degradation from a downstream transcriptional effect (Frontiers in Immunology, 2023). Target engagement can be shown the same way: cellular thermal shift assays moved DHHC3 from 49 °C in untreated cells to 55 °C in peptide-treated cells, evidence that the compound reaches the protein before any degradation is measured (Frontiers in Immunology, 2023).
That chart is the strongest quantified argument in this article for treating the E3 element as a design variable rather than an afterthought. Swapping CRBN for VHL, with the same warhead chemistry, moved DC50 from 0.103 µM to 1.92 μM, and the IAP arm to 7.530 μM (Cell Death & Disease, 2024). Nearly two orders of magnitude separate the best and worst arm in the same cellular assay.
Now the gap. The same series reports DC50 values but no Dmax, so potency is comparable across arms while the ceiling of degradation is not (Cell Death & Disease, 2024). A compound can be potent and still leave most of the target standing. When you hand a package from chemistry to biology, ask for the full dose-response curve, not the single number: functional assay support means the curve, the rescue control, and the engagement assay together, because that is what a reviewer will ask for on HIF-1α degradation or any other target you take forward.
앵커 케이스의 산소 상태 한계
The anchor cyclic peptide PROTAC restores VHL-mediated HIF-1α degradation robustly at 3% O₂, and shows no net degradation at 1% O₂. That is not a potency failure. Under the reported conditions the degrader stays engagement- and degradation-competent at 1% O₂, but the target’s resynthesis outpaces clearance, so the steady-state pool never falls (잭, 순환 펩티드 PROTAC는 저산소증에서 VHL 매개 HIF-1α 분해를 복원합니다, 2026).
Read that as a design rule rather than a footnote: a degradation readout is only interpretable against the resynthesis rate of the target in the same cellular context. A DC50 measured at one oxygen tension does not transfer to another, because the number you measured is a net balance, not a clearance constant.
Before you compare your conjugate against a published DC50, confirm the oxygen tension, the cell line, and the resynthesis behavior of the target under that same condition.
프로그램 시간을 낭비하는 일반적인 오해
Four decision errors account for most of the lost time in a cyclic peptide PROTAC design program. Each one substitutes a cheaper measurement for the question the program actually needs answered.
High HPLC purity is not a correct conjugate. A single sharp peak at 95% tells you the material is homogeneous by one detection method. It does not tell you the linker sits on the intended residue, that the stereochemistry survived conjugation, or that the E3 ligand is intact. The fix is orthogonal characterization: LC-MS for mass confirmation, and a second chromatographic or spectroscopic method that separates the conjugate from its positional isomers.
Retained target binding is not degradation achieved. A binding assay reports occupancy. Degradation requires ubiquitination, proteasomal engagement and target loss, none of which a binding readout detects. The fix is to treat binding as a gate, not an endpoint, and to require target protein quantification before claiming degradation.
A ternary complex in a biophysical assay is not cellular degradation. Ternary complex formation is necessary but not sufficient; a stable complex can still fail to ubiquitylate. The fix is to carry the claim into cells and measure target protein levels directly.
A DC50 without a Dmax is a partial potency picture. Potency and extent are separate properties, and a compound that degrades 40% of the target at saturation is a different proposition from one that clears 90%. The fix is to report both, always, from the same dose-response series.
전환을 위한 결정 프레임워크
Run these five checks in order against your own program. Each one has a failure mode attached, and each one is cheaper to fix before the next.
-
Rank candidate exit vectors empirically, not by inspection. Express the same cyclic inhibitor with the linker at two or three different positions, run the conjugate series through the target-binding assay, and let the rank order pick the winner. Failure mode: choosing the vector that looks most accessible on the model and discovering after scale-up that binding is gone.
-
Decide the route before you commit the linker. On-resin versus solution conjugation determines how much epimerization risk you carry, so treat it as a route decision rather than a late optimization. Failure mode: a conjugate that purifies cleanly but has lost the stereochemistry the binding data depended on.
-
Purify, then characterize orthogonally. RP-HPLC purity and mass confirmation answer different questions, and neither one reports on conformation. Failure mode: a single-method release criterion that passes a misfolded batch.
-
Verify folding before you spend assay budget. 원형 이색성, NMR, or a structure-sensitive binding readout confirms the conjugate still occupies the intended conformation.
-
Build the assay chain before claiming degradation. Ternary complex formation, 타겟 참여, 합성 펩티드 and a degradation readout are three separate claims, and a binary binding result supports only the first.
핵심 내용： Conformational verification is the item programs skip most often. Purity data and mass confirmation cannot tell you whether the conjugate folded correctly, so a batch can pass every analytical gate and still fail functionally.
The sequence matters more than any single step: a program that ranks vectors first and verifies conformation before assay work avoids re-synthesizing a conjugate it has already characterized.
다음 단계
If a cyclic peptide PROTAC design program is on your roadmap, the useful next move is a scoping conversation rather than a purchase decision. Bring three things: your anchor sequence and any structural data, the exit vector you have chosen or the candidates you are weighing, and the assay readouts your team will accept as evidence of degradation. Those three inputs determine whether the conversion is a straightforward linker installation or a redesign that needs new chemistry.
For teams that need a synthesis and characterization partner, MOL Changes states capabilities across solid-phase and microbial fermentation synthesis, controlled-environment purification, HPLC/MS and sterility QC, and mg-to-kg scale. That range matters most when a conjugate program moves from analytical-scale material to the quantities a functional assay series requires. 펩타이드 생산
핵심 내용： The constructs described here are research reagents. Any clinical translation requires independent validation, and nothing in this guide substitutes for your own analytical and biological confirmation.
폭로: the author’s organization provides peptide synthesis and characterization services of the kind discussed in this article.
Discuss a custom conjugate program. Share your anchor sequence, target exit vector and required assay endpoints, and request the analytical documentation package (순도법, 구배, MS confirmation and folding data) alongside a scoping call. Start a program discussion.
자주 묻는 질문
타겟에 결합된 나의 고리형 펩타이드의 공결정 구조가 없으면 어떻게 해야 하나요??
Rank candidate attachment positions empirically instead of waiting for a structure. Express the peptide with the linker at each candidate residue, then measure in sequence: preserved target affinity, ternary-complex formation with the E3 ligase, and cellular degradation. A position that tolerates substitution keeps its affinity; one that does not is disqualified. Treat narrow structure-activity relationships at a candidate position as a stop signal, because the exit vector is probably buried in the binding interface.
고리형 펩타이드 PROTAC에는 긴 링커가 항상 더 좋습니다.?
아니요. Linker length and composition change ternary-complex geometry, and that geometry drives potency in both directions. The frequently quoted 5-15 atom window comes from secondary recaps whose primary pages could not be read in this run, so treat any specific range as a starting hypothesis to test across a small series, not a specification to design against.
분석 데이터에서 접힘 문제와 에피머화를 구별하는 방법?
Use orthogonal methods, because a single RP-HPLC main peak cannot separate the two failure modes. Chiral LC or NMR resolves stereochemistry at the affected residue; circular dichroism and NMR report on solution conformation. Epimerization is a known hazard of the conjugation chemistry rather than a vendor talking point, so when peptide purity and folding both look acceptable and activity still drops, run the stereochemical check before redesigning the linker.
억제보다는 분해를 주장하기 위한 최소 분석 세트는 무엇입니까??
Four measurements: ternary-complex formation, target ubiquitination, proteasomal dependence confirmed by MG132-type rescue, and quantitative DC50 and Dmax from dose-response curves. Ternary complex alone is insufficient, since binding without ubiquitination transfer proves nothing about degradation. DC50 and Dmax alone are phenotypic: they show the target disappeared without showing the proteasome caused it. Report the set together, and state the cell line and time point for each.
